secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2024-12-02T23:59:59+00:00
Accession:  0001493152-24-048316
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Serina Therapeutics secures $10M equity financing from Juvenescence at $10/share (120% premium)
--------------------------------------------------------------------------------

- Financing of 1M shares at $10/share, a 120% premium to Nov 26 closing price.
- First $5M tranche received Nov 27, 2024; second $5M due by Jan 31, 2025.
- Proceeds to advance SER-252 (POZ-apomorphine) into Phase 1 trial in advanced Parkinson's in H2 2025.
- Juvenescence surrendered 755,728 post-merger warrants; received replacement incentive warrants exercisable at $18.
- Special committee of independent directors approved the related-party transaction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000149315224048316/0001493152-24-048316-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000149315224048316/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-048316

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer